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PURPOSE. Autosomal dominant optic atrophy (ADOA) is char-
acterized by primary degeneration of retinal ganglion cells and
atrophy of the optic nerve. The OPA1 gene encodes a 960-
amino-acid protein. In the current study the temporal and
spatial localization of OPA1 were examined in developing and
adult murine ocular tissues and the adult human eye. Because
the Bst/ mouse has been postulated as a model of ADOA, the
mOPA1 expression in the Bst/ retina was also examined.
METHODS. A polyclonal antibody generated against a C-terminal
peptide of OPA1 was used to assess by immunohistochemistry
the expression of mOPA1 in the wild-type embryonic and
postnatal mouse ocular tissues and the Bst/ retina. Western
blot analyses of total proteins from a panel of adult human
tissues were used to examine the expression of human OPA1,
and spatial localization was assessed by immunohistochemis-
try.
RESULTS. The ocular expression of mOPA1 begins at E15 in the
inner retina in a location corresponding to that of the subse-
quently developing ganglion cell layer (GCL) and peaks be-
tween postnatal day (P)0 and P1 in the retina and the optic
nerve. There is a sharp decline in mOPA1 expression after P2,
but it is expressed at a basal level until at least P12 in the GCL,
inner plexiform layer (IPL), and inner nuclear layer (INL) of the
retina as well as in the optic nerve. In the adult Bst/ retina,
mOPA1 is strongly expressed in the GCL and IPL and weakly in
the INL. In the adult human eye, OPA1 is expressed in the GCL,
IPL, INL, and outer plexiform layer (OPL) of the retina and in
the optic nerve, where it is observed only in the myelinated
region.
CONCLUSIONS. OPA1 is not restricted to the GCL of the mamma-
lian retina, and its expression extends into the IPL, INL, and
OPL. OPA1 is distinctly expressed in the myelinated region
beyond the lamina cribrosa in the human optic nerve, whereas
its expression is weaker in the mouse optic nerve. In the Bst/
mouse retina, despite the structural defects, mOPA1 expres-
sion is comparable to that observed in the wild-type adult
mouse retina. These observations suggest a wider role for
OPA1 than previously anticipated. (Invest Ophthalmol Vis Sci.
2004;45:1667–1673) DOI:10.1167/iovs.03-1093
Autosomal dominant optic atrophy (ADOA) is the mostprevalent primary hereditary optic neuropathy, with a
frequency of 1:12,000 to 1:50,000 in developed countries.1
ADOA is frequently diagnosed by 6 to 8 years of age, but cases
with nystagmus and onset as early as 1 year of age are well
recognized, confirming the congenital nature of the disease in
some patients.2 The disease is characterized by an insidious
onset of visual impairment in early childhood with moderate to
severe loss of visual acuity, temporal optic disc pallor, color
vision deficits, and centrocecal scotoma of variable density.3–5
ADOA shows variable expression ranging from asymptomatic
carriers to legally blind patients4 and is untreatable by surgical
or medical interventions. Evidence from electrophysiological
and histopathological studies shows that the fundamental un-
derlying defect is retinal ganglion cell (RGC) degeneration
followed by ascending atrophy of the optic nerve, including
loss of myelin and nerve tissue within the optic nerve.3,6–8
There are four loci for nonsyndromic optic atrophy,9–12 but
the most common is OPA1, which is attributable to mutations
in the OPA1 gene located at q28 on chromosome 3.13–16 The
OPA1 gene spans 70 to 90 kb and is composed of 31 exons.17
Northern blot analyses of OPA1 transcripts have shown the
presence of OPA1 RNA in almost all human tissues exam-
ined.13,16 The last exon is not coded, and exons 4, 4b, and 5b
generate eight isoforms of RNA by alternative splicing, with
some splicing isoforms predominating in the brain, retina,
heart, and muscle.17
OPA1 encodes a protein of 960 amino acids, which shows
homology to yeast mitochondrial dynamin-like guanosine
triphosphate (GTP) binding proteins, due to the presence of an
N-terminal leader sequence for mitochondrial localization and
central guanosine triphosphatase (GTPase) and dynamin do-
mains.13,16 The C terminus of OPA1 differs from other dynamin
family members in lacking a proline-rich region as well as
dynamin GTPase effector and pleckstrin homology domains.18
Primary structure predictions suggest a high probability of
coiled–coil formations in two separate domains encoded by
exons 5b to 7 (90%–100%) and exons 27 to 28 (95%), and these
may be involved in the formation of homodimers or polymers
or the binding of as yet unknown cellular partners. Studies in
yeast have demonstrated that native GTPases of the Mgm1/
Msp1 subfamily, which show the highest homology to OPA1,
play an important role in the dynamics of mitochondrial mor-
phology and the fusion/fission processes.19–22 Different iso-
forms of OPA1 have been sublocalized to the inner and outer
mitochondrial membranes.23,24
Several hypotheses have been put forward to explain the
pathogenic mechanisms that may play a role in OPA1-type
dominant optic atrophy. Truncating mutations in the N-termi-
nal region and missense mutations in the GTPase domain lead
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to loss of function of the protein and haploinsuffi-
ciency.17,25–27 Other mutations that result in the loss of the last
seven C-terminal amino acids or skipping of exon 27 suggest
that the last two exons encode a critical domain in OPA1
structure or function.25–28 Because exons 27 to 28 have a high
probability of forming a coiled–coil domain, which putatively
interacts with other proteins, these truncated OPA1 proteins
may be impaired in their interaction with other proteins and
exert a dominant negative effect. Although most missense and
truncating mutations have been found predominantly in the
GTPase or C-terminal regions, the pathologic effect is observed
only in the RGCs.3 This is intriguing, given the fact that OPA1
transcripts are ubiquitously expressed in all body tissues.13,16
Previous reports have speculated that this may be due to OPA1
being predominantly expressed in the RGCs26 or the RGCs’
being more susceptible to reactive oxygen species.29 To date,
there are no data to suggest a role for OPA1 in the degeneration
of the RGCs.
Patients with ADOA have a reduction in the number of
RGCs.3,6 In 1977, Southard and Eicher30 identified an autoso-
mal, semidominant mutation, belly spot and tail (Bst), which
arose spontaneously in the C57BLKS mouse strain.30 Whereas
mice homozygous for Bst die in utero, adult heterozygotes are
viable and fertile and show reduced or complete absence of
the pupillary light reflex in one or both eyes and unilateral or
bilateral atrophy of the optic nerve.31 This is similar to human
ADOA, in which patients show variable expression ranging
from asymptomatic carriers to complete blindness. As a result,
the Bst/mouse has been proposed as a mouse model of optic
atrophy.32 However, Bst/ mice also show defects such as
polydactyly and retinal coloboma and rosette formation in
addition to a decrease in the number of RGCs.31,33,34 These
studies suggested that the Bst gene may play a developmental
role in regulating cell proliferation during organogenesis.
To understand the functional role of OPA1 in normal retinal
development and to shed light on the pathogenesis of ADOA,
we examined the expression pattern of mOPA1 in the prenatal
and postnatal eyes of mouse and compared the murine expres-
sion profile with the expression of OPA1 in human ocular
tissues. We also examined the expression of mOPA1 in the
Bst/ retina compared with that in the wild-type retina.
METHODS
Preparation of Tissues
All protocols involving the use of mice adhered to the regulations set
forth in the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Experiments involving human tissue conformed to
the guidelines set forth in the Declaration of Helsinki for the use of
human tissue in research, and we had prior approval from the Moor-
fields Eye Hospital Research and Ethics Committee.
Mouse Embryos. Wild-type mouse embryos were obtained
from mating of male and female BALB/c mice. Mating was assumed to
have taken place at midnight, and the day of plug detection until the
following midnight was called embryonic day (E)0. Embryos were
dissected from pregnant females at E14, E15, E16, and E17 and fixed in
4% paraformaldehyde in phosphate-buffered saline (PBS) overnight at
4°C. Subsequently, the embryos were dehydrated and embedded in
paraffin wax for sectioning at 5 to 6 m. Two pregnant females were
used at each time point, and data were compiled from results taken
from experiments on at least three embryos from each time point.
Postnatal Mouse Eyes. Timed-pregnant C57BL/6J mice were
purchased from Harlan (Crawley Down, UK) The day of plug detection
was designated as E0. Eyes were dissected rapidly from newborn mice
starting from the day of birth (designated as PO or postnatal day [P]0)
to P12 and immediately transferred to freshly prepared 4% paraformal-
dehyde in PBS for overnight fixation at 4°C. After fixation, the eyes
were dehydrated and embedded in paraffin wax. Sections were cut at
6 m for use in immunohistochemistry. Data were compiled from
results taken from experiments on eyes from two different mice at
each time point. Adult mouse eyes were obtained from C57BL/6J mice,
fixed in 4% paraformaldehyde in PBS overnight, dehydrated, and em-
bedded in paraffin wax. Sections were cut at 6 m for use in immu-
nohistochemistry.
Bst Mouse Eyes. Eyes from 10-week-old Bst/ mice on
C57BL/6J background were obtained from the Jackson Laboratory (Bar
Harbor, ME) in 10% neutral buffered formalin. The eyes were dehy-
drated, equilibrated with xylene, and embedded in paraffin wax. Sec-
tions were cut at 6 m for use in immunohistochemistry.
Human Eye Tissue. A donor eye from a 68-year-old patient was
obtained from the Moorfields Hospital Eye Bank with full prior ap-
proval from the Moorfields Eye Hospital Research and Ethics Commit-
tee and fixed in 10% neutral-buffered formalin, within 2 hours of
enucleation, for 24 hours. The eye was dehydrated with increasing
concentrations of industrial methylated spirit (IMS), equilibrated in
xylene, and embedded in paraffin wax. Sections were cut at 6 m on
a microtome, floated on 20% methanol, expanded on water preheated
to 40°C, and mounted on glass slides.
Antibody Generation, SDS-PAGE, and
Immunoblot Analysis
A peptide corresponding to amino acids 938-960 of the human OPA1
sequence (DLKKVREIQEKLDAFIEALHQEK) was synthesized and con-
jugated to keyhole limpet hemocyanin (KLH) through an artificial Cys
placed at the N-terminal (Genosys Biotechnologies, Cambridge, UK).
Rabbit polyclonal antiserum (anti-OPA1) was obtained by subcutane-
ous injection of the conjugated peptide every 4 weeks (Genosys
Biotechnologies).
Total protein extracts from different human tissues were prepared
by homogenization in sample buffer (0.0625 M Tris-HCl, 2.5% SDS, 5%
2-mercaptoethanol, 10% glycerol, and 0.25% bromophenol blue). Total
protein concentrations in tissue extracts were assayed using the Brad-
ford microassay (Bio-Rad Laboratories, Hercules, CA) to ensure even
loading of gels. Protein samples from each extract were loaded on 12%
SDS-PAGE gels and resolved by electrophoresis. The gels were electro-
blotted onto ECL nitrocellulose (Amersham, UK). The nitrocellulose
membrane was incubated overnight in blocking solution (5% nonfat
milk powder, 1 PBS, and 0.1% Tween-20), after which the blots were
incubated with either rabbit preimmune serum or anti-OPA1 (1:2000
dilution) antibody for 1 hour at room temperature (RT). In competition
assays, the peptide (1 g/mL) against which the antiserum was gener-
ated was incubated with the anti-OPA1 antiserum (1:2000) for 30
minutes on ice before incubation with the nitrocellulose membrane for
1 hour at RT. Subsequently, the membrane was incubated with goat
anti-rabbit secondary antibody (1:30,000) conjugated to horseradish
peroxidase (Jackson ImmunoResearch Laboratories, West Grove, PA)
for 1 hour at RT. Bands were visualized by enhanced chemilumines-
cence using the ECL kit (Amersham).
Immunohistochemistry
Paraffin-embedded sections of mouse embryos, postnatal mouse eyes,
Bst/ mouse eyes, and human eye were deparaffinated with xylene and
rehydrated successively with 100%, 95%, and 70% IMS. Endogenous
peroxidase activity was blocked by incubating the sections with 0.5%
hydrogen peroxide (Sigma-Aldrich, Poole, UK) in 50% methanol for 30
minutes at RT. The sections were then blocked with 10% normal goat
serum (Dako, Ltd., High Wycombe, UK) in Tris-buffered saline (TBS)
for 20 minutes at RT, followed by incubation with anti-OPA1 antibody
(1:100 or 1:250 dilution) in TBS containing 10% normal goat serum
overnight at 4°C. Subsequently, the sections were briefly rinsed with
TBS and incubated in goat anti-rabbit antibody conjugated to horserad-
ish peroxidase (1:500; Jackson ImmunoResearch Laboratories) for 45
minutes at RT. The immunoreaction was visualized by staining with
solution containing 3,3-diaminobenzidine (DAB; Sigma-Aldrich),
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0.03% hydrogen peroxide in TBS until color development. Some sec-
tions were developed with alkaline phosphatase substrate (Vector Red;
Vector Laboratories Inc., Burlingame, CA). Subsequently, the sections
were successively dehydrated with 70%, 95%, and 100% IMS, clarified
with three changes of xylene, and mounted in dibutyl phthalate xylene
(DPX) mounting medium (Merck, Hoddesdon, UK). To verify the
specificity of the immunostaining, sections were also stained with
rabbit preimmune serum. The sections were visualized with a light
microscope (BX50; Olympus, Tokyo, Japan) using bright-field and
differential interference contrast (Nomarski) optics and photographed
with a digital camera (model DXM1200; Nikon, Tokyo, Japan).
RESULTS
Characterization of OPA1 Expression in
Human Tissues
A rabbit polyclonal antibody was raised against a KLH-conju-
gated peptide corresponding to amino acids 938 to 960 of the
predicted human OPA1 sequence. The specificity of this anti-
body (anti-OPA1) was confirmed by Western blot analysis of
total protein extracts from nine different human adult tissues
including the cerebellum, spinal cord, retina, heart, liver, and
lung.
A major band of approximately 90 kDa was detected in total
protein extracts from the human heart, lung, kidney, spinal
cord, skeletal muscle, retina, cerebellum, and testes under
reducing conditions (Fig. 1A). No protein was detected when
the total protein extract from the retina was incubated with the
anti-OPA1 antibody in the presence of the competing peptide
or by incubation with rabbit preimmune serum, indicating that
the reactivity against the 90 kDa band was specific (Fig. 1B). A
larger band of approximately 100 kDa was also detected in the
heart and spinal cord (Fig. 1A). This is consistent with a
previous report that showed that OPA1 exhibits eight RNA
isoforms as a result of alternative splicing of exons 4, 4b, and
5b and that some isoforms predominate in different tissues.17
The mature OPA1 protein has a predicted molecular weight of
approximately 106 kDa, and this may account for the 100 kDa
band that we detected in total protein extracts from the heart
and spinal cord. We also detected a 60 kDa band in the liver.
The identity of this smaller band is unclear, because it is too
small to be a known isoform of OPA1. Smaller OPA1 RNA
transcripts of approximately 4 and 3.5 kb have been reported
in the human and mouse livers, respectively, by Northern
analyses and have been attributed to alternative polyadenyla-
tion.13,16,20 In another study, the smaller 86 kDa protein band
observed in the mitochondrial fraction of rat liver using a
different anti-OPA1 antibody was attributed to posttranslational
modifications and/or aberrant conformational migration.23
Whether the 60 kDa protein currently of uncertain identity
detected by our anti-OPA1 antibody in the liver is a result of
alternative polyadenylation, or post translational modification,
or both needs to be examined further. Also, it is unclear why
only this 60 kDa band is detected in the liver.
Expression of mOPA1 in the Developing
Mouse Embryo
Because the underlying pathology in OPA1-type optic atrophy
is primary degeneration of RGCs,3 we investigated the tempo-
ral and spatial expression profile of mOPA1 in the developing
mouse retina from embryonic stages E14 to E17. We did not
see any ocular expression of mOPA1 in the E14 embryo (data
not shown). This may either reflect the absence of mOPA1 or
lack of sensitivity of immunohistochemical techniques in de-
tecting low levels of protein. At E15, mOPA1 begins to appear
in the prospective ganglion cell layer (GCL) of the developing
retina (Fig. 2B). At the E16 stage, strong expression of mOPA1
was observed in the prospective GCL as well as in the lens and
the ectoderm overlying the eye (Fig. 2C) and the brain (data
not shown). A low level of expression was also observed in the
neuroblastic layer (Fig. 2Cc). No signal was detected when the
anti-OPA1 antibody was omitted or when the sections were
stained only with rabbit preimmune serum (Fig. 2A), confirm-
ing the specificity of the mOPA1 signal. Just before birth, at
E17, mOPA1 was very strongly expressed only in the GCL of
the retina. No expression was observed in the retinal pig-
mented epithelium (Fig. 2D) or other ocular tissues. However,
strong mOPA1 expression was detected in most other body
tissues of the embryo, including the surface ectoderm, somites,
heart, liver, lung, brain (data not shown), and skeletal muscle
(Fig. 2E).
Postnatal Expression Profile of mOPA1 in Mouse
Ocular Tissues
Strong expression of mOPA1 was observed in the GCL of the
retina at P0 (Fig. 3A) and continued until the P2 stage, peaking
at P1 (Figs. 3B, 3C). At these stages, mOPA1 was found to be
strongly expressed both in the GCL and optic fiber layer of the
retina and the optic nerve (Fig. 3B, 3Bb, 3Bb). No expression
was observed in the inner plexiform layer (IPL), inner nuclear
layer (INL), outer plexiform layer (OPL), outer nuclear layer
(ONL), photoreceptors (PR), or pigmented epithelium (Figs.
3Aa, 3Bb, 3Cc). Between P4 and P8, there was a sharp decline
in the level of mOPA1 expression in the retina, although from
P4 onward, the expression spread from the GCL to the IPL and
INL (Figs. 3D, 3F, 3G). This decline was concomitant with a
drastic decrease in mOPA1 expression in the optic nerve (com-
pare Figs. 3Bb and 3E). The P12 stage coincides with the time
when the mouse eye opens. At this stage, a broad, diffused
mOPA1 signal was detected in the GCL and the IPL, and a more
FIGURE 1. (A) Immunoblot of proteins from a panel of human tissues,
using the anti-OPA1 antiserum. The antiserum detected proteins of
90 kDa in most tissues and a larger band of 100 kDa in the heart
and spinal cord. A smaller band of 60 kDa was also detected in the
liver and skeletal muscle. (B) Immunoblot of human retinal proteins
reacted with anti-OPA1 antiserum. A single band of 90 kDa was
detected in the human retina by anti-OPA1 antiserum. Rabbit preim-
mune serum did not detect the 90-kDa band, and the band was not
detected when the anti-OPA1 antiserum had been preadsorbed by the
peptide against which it was generated before immunoblot analysis.
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localized signal was detected in the INL of the mouse retina
(Fig. 3G). A weak signal was also observed in the myelinated
region of the optic nerve (data not shown). No expression was
detected in the lens or other ocular tissues at any of the
postnatal stages examined (data not shown).
Analysis of mOPA1 Expression in the Bst/
Mouse Retina
As the Bst/mouse has been proposed as a model for ADOA,32
we also examined mOPA1 expression in the adult Bst/ retina
and compared it with the expression pattern in the wild-type
adult mouse retina. In the wild-type adult mouse retina,
mOPA1 expression was detected in the GCL, IPL, INL, and
OPL, although this signal appeared to be more distinctly local-
ized in the INL than in the GCL, IPL, and OPL (Fig. 4E). Within
the adult mouse optic nerve, a weak, patchy mOPA1 signal was
detected in the myelinated region (Fig. 4F). No mOPA1 signal
was detected in the lens or any other ocular tissue (not
shown). Significantly, the weak mOPA1 expression observed
in the adult mouse eye was in contrast to its strong expression
in the mouse liver, which remained comparable to that at
embryonic stages (data not shown). The Bst/ mouse retina
showed a similar profile of mOPA1 expression, although the
spatial distribution was affected by the loss of normal structure
due to rosette formation within the Bst/ retina (Fig. 4B). It
has been reported that in severely affected Bst/ mice, the
organization of the neural retina is distorted with the inner and
outer nuclear layers thrown into folds, rosettes or colobomas
and the IPL and OPL reduced in thickness.31 All these defects
were clearly evident in a hematoxylin-eosin–stained section of
the Bst/ retina (Fig. 4A). In particular, the OPL was found to
be either absent or severely reduced. Despite these structural
defects, a strong mOPA1 signal was detected in the GCL and
the IPL, whereas a much weaker signal was seen in the INL,
surrounding the rosettes (Fig. 4C). In more structurally normal
regions of the Bst/ retina, mOPA1 signal was comparable to
that observed in the adult wild-type mouse retina (Fig. 4D). No
signal was detected in the lens or other ocular tissues of the
Bst/ eye (data not shown).
Analysis of OPA1 Expression in the Adult
Human Eye
Figure 5 shows the expression of OPA1 in different human
ocular tissues. Human OPA1 was found to be expressed not
only in the GCL, IPL, and INL but also in the OPL. Notably,
there appeared to be a distinct boundary of OPA1 expression
at the outer limit of the OPL (Fig. 5B). No expression was
detected in the ONL, PR, or the pigmented epithelium (Fig.
5B). OPA1 was also detected in the ciliary body (data not
shown), the corneal epithelium and endothelium (Fig. 5C), and
the optic nerve (Fig. 5D). Expression in the optic nerve was
detected in the myelinated region beyond the posterior limit of
the lamina cribrosa, but not in the unmyelinated prelaminar
region (Fig. 5D). No reaction products were observed when
the primary antibody was omitted or when the immunolabel-
ing was performed with only rabbit preimmune serum (data
not shown).
DISCUSSION
In this study, we examined the expression profile of OPA1 in
embryonic and adult mammalian tissues and compared the
expression of mOPA1 between wild-type adult mouse eye and
the Bst/ eye. Western blot analysis of proteins from a panel of
adult human tissues showed that OPA1 is ubiquitously ex-
pressed (Fig. 1), although some isoforms predominate in dif-
ferent tissues. The presence of OPA1 protein in different tis-
sues further corroborates previous work that reported OPA1
transcripts in different human tissues by Northern blot analysis
of multiple tissue blots.16 Our immunohistological analyses of
OPA1 expression in the adult mammalian retina revealed that it
is not expressed exclusively in the GCL. In fact, we found
OPA1 also to be expressed in the IPL, INL, and OPL of the adult
mouse and human retina. This result is intriguing in light of the
fact that ADOA is thought to be a consequence of primary
degeneration of RGCs3 and no defects in the inner and OPLs or
the INL have been reported in patients exhibiting ADOA. The
sustained expression of OPA1 in the adult mammalian retina
suggests that it may be required to perform an essential func-
tion in postnatal development.
We also determined the spatial and temporal expression
pattern of mOPA1 in the developing mouse retina, which may
provide fundamental clues to the in vivo function of OPA1 and
FIGURE 2. Expression profile of mOPA1 during mouse embryonic
development. (A) E16 embryo stained with rabbit preimmune serum
showed weak, nonspecific staining in the lens and surface ectoderm.
(B) The earliest expression of mOPA1 in the retina was observed at
E15, where it was present at a low level in the inner retina, corre-
sponding to the position of the subsequent location of the GCL (B, Cc,
and D, arrows) and the lens. (C) mOPA1 was strongly expressed at E16
as a distinct band in the presumptive GCL. Weaker staining was also
present in the lens and neuroblastic layer of the retina; (Cc) 40
magnification of the boxed area. (D) At E17, expression of mOPA1
was detected in the presumptive GCL of the retina. (E) At E17, mOPA1
was strongly expressed in most other body tissues. Shown is a sagittal
section of the skeletal muscle around the vertebrae (v). Scale bar, 100
m.
1670 Aijaz et al. IOVS, June 2004, Vol. 45, No. 6
hence help our understanding of the pathogenesis of OPA1-
type ADOA. In our study, the earliest ocular expression of
mOPA1 was detected at E15. Between E16 and E17, mOPA1
was found to be expressed very strongly in the prospective
GCL of the retina and weakly in the lens (Fig. 2). No expression
was detected in the developing photoreceptor layer, the pig-
mented epithelium, or other ocular tissues at these stages.
Expression was also detected in the lung, liver, heart, skeletal
muscle, and brain of the developing embryo. After birth, strong
mOPA1 expression continued in the GCL of the retina and in
the optic nerve until P2 and then declined sharply (Fig. 3).
Between P0 and P2, mOPA1 was localized both within the GCL
and the optic fiber layer of the retina and the optic nerve.
Between P4 and P12, although mOPA1 levels decreased in the
GCL of the retina, its expression domain was found to spread
to the IPL and INL. Beyond this stage, mOPA1 was expressed at
a weak level in the retina and optic nerve throughout life.
However, we detected a high level of mOPA1 expression in the
adult mouse liver, and Misaka et al.20 have reported high levels
of mOPA1 transcripts in the adult mouse brain, heart, lung,
liver, kidney, ovary, and skeletal muscle. Thus, the downregu-
lation in the mOPA1 signal that we observed in the eye in the
postnatal stages is in contrast to its continued high level of
expression in other body tissues. This may explain why the
pathologic effects of ADOA are seen only in the eye, despite
the ubiquitous presence of OPA1 in almost all body tissues. It
may be that the sharp decline in mOPA1 expression beyond P2
merely reflects a natural reduction in the number of RGCs by
apoptosis.35 However, the fact that OPA1 expression gradually
increases before birth and peaks shortly after birth suggests
another role for OPA1. In the mouse, RGCs are generated
between E11 and E18, and the latter age coincides with the
onset of naturally occurring RGC death.36 After E12, the RGCs
extend their axons along defined paths and establish topo-
graphically ordered connections in the central nervous system.
The first RGC axons reach the optic chiasm at E12 and their
most distal target in the midbrain, the superior colliculus, at
E14 but additional RGC axons continue to grow throughout
the optic tract and into the superior colliculus until birth.37,38
By P14, the mature retinocollicular topographic map is nor-
mally established.37 The appearance of OPA1 after E14 sug-
gests that it may play a role in RGC axon growth, pathfinding,
and/or target innervation.
Patients with ADOA have a reduced number of RGCs.3,6 A
similar reduced number of RGCs has also been reported in the
retina of the Bst/mouse.31 Approximately 60% of Bst/mice
show a reduced or complete absence of the pupillary light
reflex and atrophy of the optic nerve in one or both eyes, and
FIGURE 3. mOPA1 expression in the
mouse eye during postnatal develop-
ment. (A) mOPA1 was strongly ex-
pressed in the retina at P0 in the
GCL; (Aa) 40 magnification of the
boxed area in (A). The arrow indi-
cates the RGC layer. (B) mOPA1 ex-
pression peaked at P1, when it was
localized in the GCL and optic fiber
layer of the retina and the optic
nerve; (Bb) mOPA1 expression
(boxed area, top) in the optic nerve
at 40 magnification; (Bb) 40
magnification of the bottom boxed
area, showing mOPA1 expression in
the GCL. (C) At P2, there was a mar-
ginal decline in the level of mOPA1
expression, although it was still ex-
pressed only in the GCL; (Cc) 40
magnification of the boxed area. (D)
At P4, mOPA1 expression showed a
sharp decline and appeared as a
broad, diffuse band, not only in the
GCL, but also in the IPL and INL. (E)
At P4, there was also a decline in the
expression of mOPA1 in the optic
nerve. At P8 (F) and P12 (G), the
mOPA1 expression profile was simi-
lar, being localized in the GCL, IPL,
and INL.Scale bar, 100 m.
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older mice also show subretinal neovascularization.31,39 Until
recently, it was postulated that the mouse Bst locus was ho-
mologous to the human OPA1 gene as a result of a fractured
synteny between the OPA1 locus at q28 on human chromo-
some 3 and the Bst locus on mouse chromosome 16.32 We
therefore looked at the expression of mOPA1 in the adult
Bst/ mouse retina and compared it with that in the wild-type
adult mouse retina. Although the morphology of the Bst/
retina was severely disrupted as a result of rosette formation, a
strong mOPA1 signal was detected in the GCL and IPL,
whereas a weaker signal was observed in the INL around the
rosettes. Because the OPL in the Bst/ retina was either absent
or severely reduced, the signal in the OPL was unclear. In more
structurally normal regions, the signal was comparable to that
observed in the wild-type adult mouse retina. Therefore, the
Bst/ mouse may not be an accurate model for ADOA, as has
been previously proposed.32 Moreover, the polydactyly ob-
served in Bst/ mice has never been reported in patients with
ADOA, nor do the retinas of those with ADOA show the
neovascularization that occurs in older Bst/ mice.33,34,39 We
do not believe the Bst/ mouse to be a true model of ADOA.
In fact, while this work was in progress, Delettre et al.40
excluded the mouse opa1 from the Bst locus by radiation
hybrid mapping, confirming our results. Our results further
underline the need to develop a mouse model of ADOA to
understand the pathologic course of the disease.
Finally, in the adult human eye, we found OPA1 to be
expressed in the GCL, IPL, INL, and OPL of the retina, as well
as in the cornea, ciliary body, and optic nerve. Most notably,
within the optic nerve, OPA1 was present in the myelinated
region beyond the lamina cribrosa but not in the unmyelinated
prelaminar zone. This observation is significant, because the
mitochondrial marker, cytochrome-c oxidase has been shown
to be relatively abundant in the unmyelinated region.41 Also, a
high degree of overlap has been shown between the distribu-
tion of OPA1 and cytochrome-c in transfected COS-7 cells,20
although the OPA1 signal did not overlap that of cytochrome-c
when primary cultures of dissociated rat cerebellar cells were
used in the same study.20
Our results clearly show that at least in the adult human
optic nerve, OPA1 and cytochrome-c oxidase do not colocalize
in vivo, suggesting that despite the homology to mitochondrial
GTPases, the distribution of endogenous OPA1 may not be
confined to the mitochondria. This may also explain why we
do not observe any OPA1 in the PR layer, which is highly
metabolically active and rich in mitochondria. In the adult
mouse, weak mOPA1 expression was observed in the myelin-
ated region of the optic nerve, and although the expression did
not extend beyond the OPL in the retina, there was no distinct
boundary of mOPA1 expression at the outer limit of the OPL,
as seen in the human retina. These observations may reflect
species-specific differences in OPA1 expression between the
human and mouse eye. Thus, OPA1 may have a complex role
to play in the adult mammalian eye, and more functional
studies are needed to address its role in the pathogenesis of
ADOA.
FIGURE 5. Expression profile of OPA1 in the adult human eye. (A) A
hematoxylin-eosin–stained section of the human retina. (B) OPA1 was
expressed in the GCL, IPL, INL, and OPL of the adult human retina.
There is a boundary of OPA1 expression at the outer limit of the OPL.
No expression is detected in the ONL or the photoreceptors. (C) OPA1
is also detected in the corneal epithelium and endothelium. (D) Strong
expression of OPA1 is observed in the optic nerve where it is localized
in the myelinated region beyond the lamina cribrosa, but not in the
unmyelinated prelaminar zone. The gaps observed in the prelaminar
region were a result of sectioning. ep, epithelium; ed, endothelium; lc,
lamina cribrosa. Scale bar: (A–C) 100 m; (D) 500 m.
FIGURE 4. Comparison of mOPA1 expression in the Bst/ and wild-
type adult mouse retina. (A) Hematoxylin-eosin–stained section of the
Bst/ retina. (B) mOPA1 was strongly expressed in the GCL and IPL,
whereas a weaker signal was observed in the INL of the Bst/ retina
in the region around the rosettes (C). (D) In a more structurally normal
region, mOPA1 is strongly expressed in the GCL and IPL and weakly
expressed in the INL. Immunolabeling was detected by staining with a
red substrate in (B), (C), and (D). (E) In the wild-type adult mouse
retina, mOPA1 was localized in the GCL, IPL, INL, and OPL. (F) In the
adult mouse optic nerve, a weak mOPA1 signal was observed in the
myelinated region. Immunolabeling was detected by staining with
3,3-diaminobenzidine in (E) and (F). WT, wild type. Scale bars, 100
m.
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